DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...

New research linking dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes to an increased risk for inflammatory bowel disease (IBD) is prompting investigators to urge monitoring of ...

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...

The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a "warning and ...

Diabetics on therapies such as Merck & Co's Januvia and Boehringer Ingelheim/Eli Lilly's Trajenta may find that these class of drugs can help them reduce the risk of developing autoimmune diseases.

The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk of heart failure in patients with type 2 diabetes is uncertain, based on low quality of evidence found in a systematic review and ...